Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Steven M Bair"'
Autor:
Jakub Svoboda, Steven M. Bair, Daniel J. Landsburg, Sunita Dwivedy Nasta, Sarah J. Nagle, Stefan K. Barta, Nadia Khan, Joanne Filicko-O'Hara, Sameh Gaballa, Lauren Strelec, Elise Chong, Sheryl Mitnick, Terease S. Waite, Cara King, Hatcher Ballard, Matthew Youngman, James Gerson, John P. Plastaras, Amit Maity, Agata M. Bogusz, Stacy S. Hung, Hisae Nakamura, Reza Nejati, Christian Steidl, Megan Lim, Marco Ruella, Stephen J. Schuster
Publikováno v:
Haematologica, Vol 106, Iss 6 (2020)
We conducted a phase I/II multicenter trial using 6 cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment of patients with CD30-positive (+) B-cell lymphomas. Thirty-one
Externí odkaz:
https://doaj.org/article/6889546d44be4604bfd437aa26536340
Autor:
Geoffrey Shouse, Andy Kaempf, Max J. Gordon, David Yashar, Audrey M. Sigmund, Gordon Smilnak, Steven M. Bair, Agrima Mian, Lindsey A. Fitzgerald, Amneet Bajwa, Samantha Jaglowski, Neil Bailey, Mazyar Shadman, Krish Patel, Deborah M. Stephens, Manali Kamdar, Brian T. Hill, Jordan Gauthier, Reem Karmali, Loretta J. Nastoupil, Adam S Kittai, Alexey V Danilov
Publikováno v:
Blood. 140:2048-2050
Autor:
Geoffrey Shouse, Andy Kaempf, Max J Gordon, Andrew S Artz, David Yashar, Audrey M Sigmund, Gordon Smilnak, Steven M Bair, Agrima Mian, Lindsey A. Fitzgerald, Amneet Bajwa, Samantha M Jaglowski, Neil Bailey, Mazyar Shadman, Krish Patel, Deborah M. Stephens, Manali Kamdar, Brian T. Hill, Jordan Gauthier, Reem Karmali, Loretta J. Nastoupil, Adam S Kittai, Alexey V Danilov
Publikováno v:
Blood Advances.
Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability of response and prevalent toxicities remain problematic. Identifying patient
Autor:
Bradley M. Haverkos, Jasmine Zain, Manali K. Kamdar, Alexander Neuwelt, Eduardo Davila, Xander Bradeen, Steven M. Bair, Jagar Jasem, Emily Berens, Clayton Smith, Diana Abbott, Pierluigi Porcu
Publikováno v:
Blood. 140:2308-2309
Autor:
Reza Nejati, Sheryl Mitnick, James N. Gerson, John P. Plastaras, Amit Maity, Hisae Nakamura, Sarah J. Nagle, Matthew R. Youngman, Stacy Hung, Sameh Gaballa, Joanne Filicko-O'Hara, Lauren E. Strelec, Steven M. Bair, Cara M King, Terease S. Waite, Hatcher J. Ballard, Daniel J. Landsburg, Stephen J. Schuster, Elise A. Chong, Nadia Khan, Marco Ruella, Stefan K. Barta, Agata M. Bogusz, Christian Steidl, Megan S. Lim, Sunita D. Nasta, Jakub Svoboda
Publikováno v:
Haematologica
We conducted a phase I/II multicenter trial using six cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment of patients with CD30-positive B-cell lymphomas. Thirty-one pa
Autor:
James Godfrey, Pallawi Torka, Sonali M. Smith, Suman Paul, Madelyn Burkart, Raoul Santiago, Robert T. Chen, Ranjana H. Advani, Frederick Lansigan, Alex F. Herrera, Catherine Wei, Julio C. Chavez, Sarit Assouline, Reem Karmali, Kevin A. David, N Nina Wagner-Johnston, Catherine Diefenbach, Jakub Svoboda, Steven M. Bair, Sarah Tomassetti, Yang Liu, Daniel O. Persky, Lukas Emery, Sunita Nathan, Reid W. Merryman, Nicole A. Carreau, Muhammad Hamid, Andrea B. Troxel, Philippe Armand, Stefan K. Barta, Radhakrishnan Ramchandren, Jonathan B. Cohen, Michael A. Spinner
Publikováno v:
Oncologist
Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore perfo
Autor:
Geoffrey Shouse, Andy Kaempf, Max Gordon, David Yashar, Audrey M Sigmund, Gordon Smilnak, Steven M Bair, Agrima Mian, Lindsey Fitzgerald, Amneet Bajwa, Samantha Jaglowski, Neil Bailey, Mayzar Shadman, Krish Patel, Deborah M Stephens, Manali Kamdar, Brian T Hill, Jordon Gauthier, Reem Karmali, Loretta Nastoupil, Adam S Kittai, Alexey V Danilov
Publikováno v:
Blood Cancer Discovery. 3:A27-A27
Introduction: CAR T-cell therapy (CART) has dramatically improved outcomes for patients (pts) with relapsed/refractory (r/r) DLBCL, but the majority of pts still have poor outcomes due to progressive disease and toxicities. Here we used a machine lea
Autor:
Orrin Pail, Kevin A. David, Frederick Lansigan, Yang Liu, Reid W. Merryman, James Godfrey, Michael A. Spinner, Madelyn Burkart, Muhammad Saad Hamid, Robert T. Chen, Raoul Santiago, Yuhe Xia, Catherine Wei, Steven M. Bair, Catherine Diefenbach, Suman Paul, Sonali M. Smith, Philippe Armand, Nicole A. Carreau, Pallawi Torka, Alex F. Herrera, Sarah Tomassetti, Julio C. Chavez, Daniel O. Persky, Andrea B. Troxel, Sunita Nathan, Lukas Emery, Nina D. Wagner-Johnston, Ranjana H. Advani, Radhakrishnan Ramchandren, Stefan K. Barta, Reem Karmali, Sarit Assouline, Jakub Svoboda
Publikováno v:
Oncologist
Background Targeted therapies and checkpoint blockade therapy (CBT) have shown efficacy for patients with Hodgkin lymphoma (HL) in the relapsed and refractory (R/R) setting, but once discontinued due to progression or side effects, it is unclear how
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6e99d6eef560fdf8ddb6ff1a735a901
https://europepmc.org/articles/PMC7543382/
https://europepmc.org/articles/PMC7543382/
Autor:
Radhakrishnan Ramchandren, Michael A. Spinner, Raoul Santiago, Ranjana H. Advani, Pallawi Torka, Sunita Nathan, Frederick Lansigan, Reid W. Merryman, Reem Karmali, Sarit Assouline, Alex F. Herrera, Philippe Armand, Steven M. Bair, Stefan K. Barta, Jakub Svoboda, Nicole A. Carreau, Muhammad Saad Hamid, Kevin A. David, Yuhe Xia, Nina D. Wagner-Johnston, Julio C. Chavez, Catherine Diefenbach, Suman Paul, Daniel O. Persky, James Godfrey
Publikováno v:
British journal of haematologyReferences. 191(1)
Patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) have limited options for salvage, and checkpoint blockade therapy (CBT) has little efficacy. Usage in solid malignancies suggests that CBT sensitises tumours to subsequent chemotherap
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 18:380-391
Classical Hodgkin lymphoma (cHL) is one of the most common lymphomas in the Western world. Although most patients are cured with standard first-line therapy, up to 20% of patients will have relapsed or refractory disease. Although the conventional ap